PepGen Inc., a clinical-stage biotechnology company, has appointed Kasra Kasraian, PhD, as its new Chief Technology Officer. Dr. Kasraian brings over 25 years of experience in product and process development and previously held senior roles at bluebird bio and other biotech firms. His expertise will support PepGen's efforts to advance oligonucleotide therapies for severe neuromuscular and neurological diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.